Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer-Reference-Cited by-同舟云学术

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer

Published:2016-01 Issue:3 Volume:14 Page:429-439
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Choi Young Eun,Meghani Khyati,Brault Marie-Eve,Leclerc Lucas,He Yizhou J.,Day Tovah A.,Elias Kevin M.,Drapkin Ronny,Weinstock David M.,Dao Fanny,Shih Karin K.,Matulonis Ursula,Levine Douglas A.,Konstantinopoulos Panagiotis A.,Chowdhury Dipanjan

Funder

NIAID

NCI

American Cancer Society

Leukemia and Lymphoma Society Scholar Grant

Claudia Adams Barr Program for Innovative Cancer Research

Breast SPORE Pilot Award

Robert and Deborah First Fund

Mary Kay Foundation

Susan Smith Center for Women’s Cancers

Department of Defense Ovarian Cancer Academy Award

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference31 articles.

1. The Ku heterodimer and the metabolism of single-ended DNA double-strand breaks;Balestrini;Cell Rep.,2013

2. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair;Bennardo;PLoS Genet.,2008

3. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection;Boersma;Nature,2015

4. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers;Bouwman;Nat. Struct. Mol. Biol.,2010

5. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks;Bunting;Cell,2010

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug resistance in ovarian cancer: from mechanism to clinical trial;Molecular Cancer;2024-03-28

2. BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges;Frontiers in Oncology;2024-03-13

3. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors;Cancer Drug Resistance;2024-02-28

4. Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous ovarian cancer;2024-02-05

5. microRNA-622 upregulates cell cycle process by targeting FOLR2 to promote CRC proliferation;BMC Cancer;2024-01-02